Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Research

• Publication date

  2005-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-04-4391PMID 15805287
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004influential reference
• Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis

  2004cited by this paper
• The MAP kinase pathway is required for entry into mitosis and cell survival

  2004cited by this paper
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

  2004cited by this paper
• The Role of Erlotinib (Tarceva, OSI 774) in the Treatment of Non-Small Cell Lung Cancer

  2004cited by this paper
• Mitogen-activated protein kinases in apoptosis regulation

  2004cited by this paper
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004influential reference
• Inhibition of Ligand-independent ERK1/2 Activity in Kidney Proximal Tubular Cells Deprived of Soluble Survival Factors Up-regulates Akt and Prevents Apoptosis*

  2004cited by this paper
• Cooperative Regulation of the Cell Division Cycle by the Protein Kinases RAF and AKT

  2004cited by this paper
• Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

  2004cited by this paper
• In Vitro and in Vivo Metabolism of the Anti-Cancer Agent CI-1040, a MEK Inhibitor, in Rat, Monkey, and Human

  2004cited by this paper
• Anti-Angiogenic Activity of Contortrostatin, a Disintegrin from Agkistrodon Contortrix Contortrix Snake Venom

  2004cited by this paper
• Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper
• The Role of Gefitinib in Lung Cancer Treatment

  2004cited by this paper
• Oncogenic B-Raf mutations: crystal clear at last.

  2004cited by this paper
• Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery.

  2004cited by this paper
• Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.

  2004cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• Sequence Dependent Exposure of Mammary Carcinoma Cells to Taxotere® and the MEK1/2 Inhibitor U0126 Causes Enhanced Cell Killing In Vitro

  2003cited by this paper
• CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

  2003cited by this paper
• Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2003influential reference
• The dark side of Ras: regulation of apoptosis

  2003cited by this paper
• A requirement for MAP kinase in the assembly and maintenance of the mitotic spindle

  2003cited by this paper
• Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects

  2002cited by this paper
• Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.

  2002cited by this paper
• Protein kinases — the major drug targets of the twenty-first century?

  2002cited by this paper
• Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

  2002influential reference
• ERK5 MAPK Regulates Embryonic Angiogenesis and Acts as a Hypoxia-sensitive Repressor of Vascular Endothelial Growth Factor Expression*

  2002cited by this paper
• Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants

  2002cited by this paper
• Regulation of Raf-Akt Cross-talk

  2002cited by this paper
• Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions.

  2001cited by this paper
• Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway

  2001cited by this paper
• Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines.

  2001influential reference
• MEK Inhibition Enhances Paclitaxel-induced Tumor Apoptosis*

  2000cited by this paper
• Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.

  2000cited by this paper
• Phosphorylation and regulation of Raf by Akt (protein kinase B).

  1999cited by this paper
• Activation of the Mitogen-activated Protein Kinase ERK1 during Meiotic Progression of Mouse Pachytene Spermatocytes*

  1999cited by this paper
• Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

  1999cited by this paper
• Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt.

  1999cited by this paper
• Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

  1999cited by this paper
• Direct Inhibition of Cyclooxygenase-1 and -2 by the Kinase Inhibitors SB 203580 and PD 98059

  1998cited by this paper
• Active MAP Kinase in Mitosis: Localization at Kinetochores and Association with the Motor Protein CENP-E

  1998cited by this paper
• Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice

  1997cited by this paper
• Mitogen-activated protein kinase/extracellular signal-regulated kinase 2 regulates cytoskeletal organization and chemotaxis via catalytic and microtubule-specific interactions.

  1997cited by this paper
• Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.

  1997cited by this paper
• Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs.

  1996cited by this paper
• Association of mitogen-activated protein kinase with the microtubule cytoskeleton.

  1995cited by this paper
• MAP kinase becomes stably activated at metaphase and is associated with microtubule-organizing centers during meiotic maturation of mouse oocytes.

  1993cited by this paper
• Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells.

  1992cited by this paper

• Mechanisms of Gemcitabine Resistance in Pancreatic Cancer

  2026cites this paper
• A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.

  2024cites this paper
• Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma

  2023cites this paper
• Establishment of a novel method to assess MEK1/2 inhibition in PBMCs for clinical drug development

  2022influential citation
• The Route to ‘Chemobrain’ - Computational probing of neuronal LTP pathway

  2019cites this paper
• Identification of Functional MKK3/6 and MEK1/2 Homologs from Echinococcus granulosus and Investigation of Protoscolecidal Activity of Mitogen-Activated Protein Kinase Signaling Pathway Inhibitors In Vitro and In Vivo

  2018cites this paper
• Saponins isolated from Schizocapsa plantaginea inhibit human hepatocellular carcinoma cell growth in vivo and in vitro via mitogen-activated protein kinase signaling.

  2018cites this paper
• 4 Pathogenesis of Renovascular Hypertension : Challenges and Controversies

  2018cites this paper
• A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer

  2017cites this paper
• Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents

  2017cites this paper
• Pro-apoptotic effects of rHSG on C6 glioma cells

  2016cites this paper
• Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCε/δ-induced ERK pathways.

  2016cites this paper
• Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.

  2016cites this paper
• Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents

  2016cites this paper
• MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer

  2016cites this paper
• Voies de signalisation impliquées dans la sensibilisation des tumeurs mammaires au docétaxel par les acides gras polyinsaturés n-3

  2015cites this paper
• The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines

  2015cites this paper
• A New 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) Derivative Overcomes Paclitaxel Resistance by Inhibiting MAPK Signaling and Increasing Paclitaxel Accumulation in Breast Cancer Cells

  2014cites this paper
• APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction.

  2014cites this paper
• Insulin-like growth factor 2 promotes ovarian cancer growth and resistance to traditional chemotherapy.

  2014cites this paper
• Inhibition of MEK sensitizes gastric cancer cells to TRAIL-induced apoptosis.

  2014cites this paper
• Comparison of cancer cell survival triggered by microtubule damage after turning Dyrk1B kinase on and off.

  2014cites this paper
• Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

  2014influential citation
• Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition

  2013cites this paper
• The Role of the Rho GEF Arhgef2 in RAS Tumorigenesis

  2013cites this paper
• Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.

  2013cites this paper
• Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

  2012cites this paper
• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

  2012cites this paper
• Pathogenesis of Renovascular Hypertension: Challenges and Controversies

  2012cites this paper
• Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems.

  2012cites this paper
• Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells

  2012cites this paper
• The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

  2012cites this paper
• Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

  2012cites this paper
• Up-regulation of Pro-apoptotic Protein Bim and Down-regulation of Anti-apoptotic Protein Mcl-1 Cooperatively Mediate Enhanced Tumor Cell Death Induced by the Combination of ERK Kinase (MEK) Inhibitor and Microtubule Inhibitor*

  2012cites this paper
• The PI3K/AKT/mTOR Signaling Pathway: Implications in the Treatment of Breast Cancer

  2011cites this paper
• MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.

  2011cites this paper
• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

  2011cites this paper
• Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.

  2011cites this paper
• Inhibition of Ras for cancer treatment: the search continues.

  2011cites this paper
• Retrovirus-mediated multidrug resistance gene (MDR1) overexpression inhibits chemotherapy-induced toxicity of granulosa cells.

  2011cites this paper
• Systems Biology of the MAPK1,2 Network

  2010cites this paper
• Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models

  2010cites this paper
• Both Gene Amplification and Allelic Loss Occur at 14q13.3 in Lung Cancer

  2010cites this paper
• Suppression of histone deacetylase 3 (HDAC3) enhances apoptosis induced by paclitaxel in human maxillary cancer cells in vitro and in vivo.

  2010cites this paper
• Vitamin A family compounds, estradiol, and docetaxel in proliferation, apoptosis and immunocytochemical profile of human ovary endometrioid cancer cell line CRL-11731.

  2010cites this paper
• Emerging MEK inhibitors

  2010cites this paper
• Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer

  2010cites this paper
• Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts

  2010cites this paper
• The future of targeted therapy approaches in melanoma

  2009cites this paper
• Matrix Metalloproteinase–Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro Morphogenesis

  2009cites this paper
• Integrating BRAF/MEK inhibitors into combination therapy for melanoma

  2009cites this paper
• PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.

  2009cites this paper
• Investigating the role of ERK in microtubule-interfering agent-induced cell survival and death

  2009cites this paper
• Critical role of bad phosphorylation by Akt in cytostatic resistance of human bladder cancer cells.

  2009cites this paper
• Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.

  2008cites this paper
• The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

  2008cites this paper
• A Summary of Meeting Highlights

  2008cites this paper
• Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo

  2008cites this paper
• Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

  2008cites this paper
• Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules.

  2008cites this paper
• Differential impact of fibroblasts on the efficient cell death of lung cancer cells induced by paclitaxel and cisplatin

  2008cites this paper
• A genomic and expression study of AP‐1 in primary cutaneous T‐cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS

  2008cites this paper
• Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review).

  2008cites this paper
• Melanoma cell sensitivity to Docetaxel‐induced apoptosis is determined by class III β‐tubulin levels

  2008cites this paper
• Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: Implications for broad anti-tumor efficacy

  2008cites this paper
• 2007 Annual Meeting of the National Lung Cancer Partnership: a summary of meeting highlights.

  2008cites this paper
• The role of PARP-1 induced AKT activation in cytostatic resistance

  2008cites this paper
• Somatic genetics and targeted therapies for cutaneous melanoma

  2008cites this paper
• Putative allosteric MEK1 and MEK2 inhibitors

  2008cites this paper
• New small-molecule inhibitors of mitogen-activated protein kinase kinase

  2008cites this paper
• Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy

  2008cites this paper
• Ras/Raf/MEK Inhibitors

  2008cites this paper
• Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.

  2008cites this paper
• Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

  2008cites this paper
• Tumor Regression When Combined with Docetaxel ( ARRY-142886 ) Induces Growth Arrest in Melanoma Cells Signal-Regulated Kinase Kinase Inhibitor AZD 6244 The Mitogen-Activated Protein / Extracellular

  2007cites this paper
• AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

  2007cites this paper
• Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.

  2007cites this paper
• Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.

  2007cites this paper
• Mechanisms and Modulation of Neuropathic Pain by Neurotrophin-3

  2007cites this paper
• Regulation of Docetaxel-Induced Apoptosis of Human Melanoma Cells by Different Isoforms of Protein Kinase C

  2007cites this paper
• Targeting the PI3K and MAPK pathways to treat Kaposi’s sarcoma-associated herpes virus infection and pathogenesis

  2007cites this paper
• Microtubules in apoptosis induction: are they necessary?

  2007cites this paper
• Simultaneous inhibition of the mitogen‐activated protein kinase kinase and phosphatidylinositol 3′‐kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma

  2007cites this paper
• Docetaxel-Induced Apoptosis of Human Melanoma Is Mediated by Activation of c-Jun NH2-Terminal Kinase and Inhibited by the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase 1/2 Pathway

  2007cites this paper
• Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel

  2006cites this paper
• Molecular genetics and targeted therapies for cutaneous melanoma

  2006cites this paper
• Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.

  2006cites this paper
• Profile of Susan Band Horwitz

  2006cites this paper
• Paclitaxel prodrugs: toward smarter delivery of anticancer agents.

  2006cites this paper
• Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.

  2006cites this paper
• Targeting the ERK signaling pathway in cancer therapy

  2006cites this paper
• Novel targets in solid tumors: MEK inhibitors.

  2006cites this paper
• Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint

  2006cites this paper
• Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.

  2006cites this paper
• MEK1/2 inhibition promotes Taxotere® lethality in mammary tumors in vivo

  2006cites this paper
• Combined Inhibition of Chk1 and MEK1/2 Leads to Tumor Cell Death In Vivo

  2005cites this paper
• Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor re-growth

  2005cites this paper
• Oncotargets and Therapy Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Targeted Delivery of Albumin Bound Paclitaxel in the Treatment of Advanced Breast Cancer

  year unknowncites this paper